SALT LAKE CITY, August 31, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or Co-Dx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be exhibiting at the upcoming Medical Fair Asia 2022 to be held August 31-September 2 at Marina Bay Sands in Singapore.
South East Asia The most established trade show for the medical and healthcare industry is expected to welcome more than 14,000 visitors from 70 counties and regions, and is open to medical specialists, medical trade business executives and other relevant professionals involved. in industry. The Company expects the show to provide the Company’s representatives and distributors with the opportunity to showcase co-diagnostics products to a wide range of international customers and strengthen the Company’s distributor reach across Asia.
To learn more about the conference, including in-person and virtual registration details, please visit www.medicalfair-asia.com. Attendees interested in learning more about the company and its products, including its upcoming point-of-care and home rapid PCR diagnostic platform, are invited to visit Booth #2G01.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets advanced diagnostic technologies. The Company’s technology is used for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in areas other than infectious diseases and license the use of these tests to specific customers.